$9.20
0.54%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US04301G2012
Symbol
ARTL

Artelo Biosciences Inc Stock price

$9.05
-0.88 8.86% 1M
+3.05 50.83% 6M
+2.69 42.30% YTD
+1.25 16.03% 1Y
-14.29 61.23% 3Y
-62.94 87.43% 5Y
+1.05 13.13% 10Y
+1.05 13.13% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.20 2.16%
ISIN
US04301G2012
Symbol
ARTL
Industry

Key metrics

Basic
Market capitalization
$12.0m
Enterprise Value
$10.7m
Net debt
positive
Cash
$2.1m
Shares outstanding
700.0k
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
60.8%
Return on Equity
-344.1%
ROCE
780.4%
ROIC
408.4%
Debt/Equity
-0.6
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-10.5m | $-10.7m
Net Income
$-10.5m | $-6.6m
Free Cash Flow
$-5.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
3.8% | -7.1%
Net Income
-0.7% | 33.2%
Free Cash Flow
42.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-18.3
FCF per Share
$-7.8
Short interest
2.4%
Employees
6
Rev per Employee
$0.0
Show more

Is Artelo Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Artelo Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Artelo Biosciences Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Artelo Biosciences Inc forecast:

Buy
88%
Hold
13%

Financial data from Artelo Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.48 4.48
10% 10%
-
- Research and Development Expense 6.06 6.06
12% 12%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -11 -11
4% 4%
-
Net Profit -11 -11
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about Artelo Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Artelo Biosciences Inc Stock News

Neutral
GlobeNewsWire
33 minutes ago
Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain at 12 Weeks vs −5.4% Mean Weight Loss on Placebo Safety Results Showed ART27.13 was Well Tolerated SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE...
Neutral
GlobeNewsWire
9 days ago
Safety and Pharmacokinetic Data Support Dosing of ART26.12 in Fed or Fasted Conditions Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances ART26.12 Toward Multiple Ascending Dose Trial SOLANA BEACH, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) --  Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating li...
Neutral
GlobeNewsWire
21 days ago
SOLANA BEACH, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ende...
More Artelo Biosciences Inc News

Company Profile

Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.

Head office United States
CEO Gregory Gorgas
Employees 6
Founded 2011
Website artelobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today